Ocular Therapeutix Investor Relations Material

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company offers Rhopressa (generic name: tetrahydroprochlorothiazide/timolol maleate) for the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.